BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Down 79.5% in July

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 190,323 shares, a decline of 79.5% from the June 30th total of 929,023 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 8,831,855 shares, the days-to-cover ratio is presently 0.0 days.

BiomX Price Performance

Shares of PHGE stock opened at $0.19 on Friday. The business has a fifty day moving average of $0.55 and a 200 day moving average of $2.61. BiomX has a 1 year low of $0.18 and a 1 year high of $13.70. The firm has a market capitalization of $2.23 million, a price-to-earnings ratio of -0.06 and a beta of 1.30.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings results on Wednesday, May 20th. The company reported $7.38 earnings per share for the quarter. As a group, equities research analysts expect that BiomX will post -5.85 earnings per share for the current year.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by hedge funds and other institutional investors.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.